A Phase 1 Crossover Study to Assess the Bioequivalence of Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Subjects
Latest Information Update: 06 Jul 2021
At a glance
- Drugs Isavuconazonium (Primary) ; Isavuconazonium
- Indications Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses; Zygomycosis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Global Development
- 28 Jun 2021 Results published in the Antimicrobial Agents and Chemotherapy
- 25 Oct 2020 Primary endpoint (PK of isavuconazole in plasma: maximum concentration (Cmax)), has been met according to results presented at the IDWeek 2020
- 25 Oct 2020 Primary endpoint (PK of isavuconazole in plasma: area under the concentration-time curve from 0 to 72 hours (AUC72)), has been met according to results presented at the IDWeek 2020